Breaking News

Evonik, U.S. Govt. Invest $220M in Lipid Production Facility for mRNA-based Therapies

Tippecanoe site in Lafayette, IN, will enable flexible production of lipids.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evonik, a provider of drug delivery technologies, is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the U.S. The new plant at Evonik’s Tippecanoe site in Lafayette, IN, will position the company for future growth in novel mRNA-based therapies beyond COVID-19 vaccines. Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025. The investment into the lipid facility will help create more than 80 highly skilled jobs in t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters